Enliven Therapeutics (NASDAQ:ELVN) Director Sells $32,201.40 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard Heyman sold 1,230 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the completion of the sale, the director directly owned 22,647 shares of the company’s stock, valued at approximately $592,898.46. The trade was a 5.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Enliven Therapeutics Price Performance

Enliven Therapeutics stock traded down $0.21 during midday trading on Thursday, hitting $26.16. The company’s stock had a trading volume of 1,036,079 shares, compared to its average volume of 1,269,133. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -14.22 and a beta of 0.34. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $30.22. The company has a 50-day moving average price of $22.66 and a two-hundred day moving average price of $21.10.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds have recently added to or reduced their stakes in ELVN. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after buying an additional 594 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the period. Quantbot Technologies LP boosted its position in shares of Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares in the last quarter. AlphaQuest LLC bought a new position in shares of Enliven Therapeutics during the 3rd quarter worth about $96,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of Enliven Therapeutics by 194.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after buying an additional 3,490 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have weighed in on ELVN. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.